BioSpace News Archive

Resident and alumni companies also added 737 new jobs in 2020 - an increase of 56% over the previous year - and bringing the total added through LabCentral companies since 2013 to 3,132

DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, announced today the publication of a study in Nature Scientific Reports that demonstrates that DiaCarta’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients

Imvax, Inc., an emerging oncology leader that is revolutionizing immunotherapy for patients with Glioblastoma (GBM) and other cancers, announced today the appointment of Sean Hemingway as the company’s Chief Operating Officer (COO).

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference.

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce, further to its news release dated January 26, 2021, that it has completed the acquisition of GCO Packaging and Manufacturing Ltd., acquiring 100% of the outstanding shares of GCO in exchange for an aggregate of 6,000,000 common shares of Havn Life.

The advent of Artificial Intelligence and inclination towards online medical practice have been driving the mobile continuous patient monitor market

Surging cases of COPD and cardiovascular diseases is encouraging clinicians and manufacturers to develop AI driven MR vital sign monitors

Unceasing clinical trials to discover potential orally injectable drugs is likely to spur market growth prospects

The transition from stainless-steel bioreactors to single-use bioreactors, as well as increased investment on research and development activities by biotechnology and pharmaceutical companies, are likely to drive growth of the global microcarrier market in the years to come.

Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy (SMA)